BioCentury
ARTICLE | Clinical News

Replicor HBV combo leads to functional control

October 23, 2017 9:01 PM UTC

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a led to functional disease control in eight of 10 patients. Replicor CSO Andrew Vaillant told BioCentury the company plans to start a U.S. Phase II trial of the combination next year.

The open-label trial defined functional control as hepatitis B surface antigen (HBsAg) levels of less than one IU/mL and HBV DNA levels of less than 10 IU/mL. Because nucleoside analogs already reduce HBV DNA, Replicor believes the key to a functional cure is adding HBsAg blockade and using interferon to provide an immune boost (see BioCentury, Aug. 11)...

BCIQ Company Profiles

Replicor Inc.